NCT06241560View on ClinicalTrials.gov

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

February 18, 2026

Study Completion Date

February 20, 2026

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

BI 1015550

BI 1015550

DRUG

Pirfenidone

Pirfenidone

Trial Locations (2)

160

"LTD Aversi clinic", Tbilisi

0180

LTD The First Medical Center, Tbilisi

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY